TCRX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer...

Stats
Dagens volum	92 052.00
Gjennomsnittsvolum	196 857
Markedsverdi	319.19M
EPS	$0 ( 2024-03-13 )
Neste inntjeningsdato	( $-0.250 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.42
ATR14	$0.0240 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Baker Bros. Advisors Lp	Buy	8 851 451	Warrants to purchase Common Stock
2024-04-19	Baker Bros. Advisors Lp	Buy	825 968	Warrants to purchase Common Stock
2024-04-19	Lynx1 Capital Management Lp	Buy	5 000 000	Pre-funded Warrant (right to buy)
2024-02-01	Amello Jason	Buy	750 000	Stock Option (Right to Buy)
2024-01-29	Amello Jason	Buy	0

INSIDER POWER
99.17
Last 93 transactions
Buy: 66 481 256 \| Sell: 5 443 695

Volum Korrelasjon

Lang: -0.10 (neutral)

Kort: -0.69 (moderate negative)

Signal:(43.678) Neutral

TScan Therapeutics, Inc. Korrelasjon

10 Mest positive korrelasjoner
CRSA	0.871
HALL	0.871
MVBF	0.868
SNCR	0.859
OSMT	0.857
MYNA	0.84
SOUN	0.839
KFRC	0.824
LMFA	0.823
LMNL	0.819

10 Mest negative korrelasjoner
SLVO	-0.879
BNIXU	-0.864
BMRN	-0.85
ARTNA	-0.848
MRNA	-0.839
FNKO	-0.838
CAMP	-0.836
FNWD	-0.823
AVDX	-0.815

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

TScan Therapeutics, Inc. Korrelasjon - Valuta/Råvare

0.18
( neutral )

0.16
( neutral )

0.00
( neutral )

0.30
( neutral )

0.06
( neutral )

-0.33
( neutral )

TScan Therapeutics, Inc. Økonomi

Annual	2023
Omsetning:	$21.05M
Bruttogevinst:	$15.69M (74.53 %)
EPS:	$-1.360

FY	2023
Omsetning:	$21.05M
Bruttogevinst:	$15.69M (74.53 %)
EPS:	$-1.360

FY	2022
Omsetning:	$13.54M
Bruttogevinst:	$8.40M (62.05 %)
EPS:	$-2.74

FY	2021
Omsetning:	$10.14M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-4.17

Financial Reports:

No articles found.

TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.